We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 29 juni 2017

The Lancet: [Articles] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metas...

[Articles] Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms and functioning from baseline to weeks 9 and 15, whereas investigator's choice led to clinically meaningful deterioration. Nivolumab delayed time to deterioration of patient-reported quality-of-life outcomes compared with single-agent therapy of investigator's choice in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in this population and the importance of maintaining or improving quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivolumab as a new standard-of-care option in this setting.
Read more

[Comment] Hypoxia-activated prodrug: an appealing preclinical concept yet lost in clinical translation
Hypoxia-activated prodrugs use hypoxia, an inherent feature of solid tumours that drives tumour aggressiveness and chemoresistance, for tumour targeting. Preclinical studies1 with the hypoxia-activated prodrug evofosfamide (TH-302) in mice with various human tumour xenograft models have successfully proven the concept of increased antitumour activity under reduced oxygen concentration breathing conditions. A study2 in mice with non-small cell lung cancer xenografts comparing evofosfamide with the structurally related agent ifosfamide—another prodrug that is continuously activated in the liver and is established in the treatment of soft-tissue sarcoma—suggested evofosfamide had higher antitumour activity and a more favourable safety profile than ifosfamide.
Read more

[News] Some chemicals that cause tumours of the urinary tract in rodents
In June, 2017, 21 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their critical review and evaluation of the carcinogenicity of melamine, 1-tert-butoxypropan-2-ol, β-myrcene, furfuryl alcohol, pyridine, tetrahydrofuran, and vinylidene chloride. These assessments will be published in volume 119 of the IARC Monographs.1
Read more

[Articles] Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemotherapy in young patients with diffuse large B-cell lymphoma at high risk. However, these results might not be clinically meaningful, since this improvement did not reflect an improvement in overall survival. These results do not support further consideration of the use of intensification of R-CHOP as an upfront strategy in patients with diffuse large B-cell lymphoma with poor prognosis.
Read more

[News] Savolitinib for -driven papillary renal cell carcinoma
Patients with advanced papillary renal cell carcinoma harbouring MET alterations could respond to treatment with the selective MET tyrosine kinase inhibitor savolitinib, according to the results of a recent clinical trial.
Read more